Eribulin mesylate is a pharma-grade active pharmaceutical ingredient supplied as a synthetic macrocyclic ketone analogue of halichondrin B. The product model designation is the mesylate salt of eribulin, available in injectable-grade and oral solid-intermediate development grades; the technical identity is fixed by CAS 441045-17-6, the molecular formula C40H59NO11·CH4O3S, and a reported molecular weight of 826.0 g/mol. The API is manufactured under GMP expectations described in ICH Q7 and is intended for development of sterile injectable solutions and investigational tablets, capsules, and granules. The commercially established route is intravenous; no oral finished dosage form of eribulin mesylate has been approved in major regulatory jurisdictions as of the latest public assessments. Injectable-grade material is differentiated from oral-solid development grade by particulate, endotoxin, sterility, and environmental monitoring controls, while the chemical identity and tubulin-binding mechanism remain unchanged.

How Does the Tubulin-Binding Mechanism Differ From Paclitaxel, Vinorelbine, and Maytansine-Based Agents?

At the target site, eribulin mesylate binds to β-tubulin in a vinca-proximal site that is not identical to the paclitaxel site. The binding suppresses microtubule polymerization by inhibiting tubulin-dependent GTP hydrolysis and causes sequestration of tubulin into nonproductive aggregates. This mode is distinct from paclitaxel, which stabilizes microtubules and promotes tubulin polymerization, and from vinorelbine, which binds to the vinca domain and promotes depolymerization. As a result, eribulin mesylate retains activity in some nonclinical models resistant to taxanes, although the clinical relevance of this observation depends on tumor type and prior treatment burden.

The free drug is not approved for oral use, and published data for oral permeability, efflux ratio, and absolute bioavailability of eribulin mesylate are limited. This contrasts with vinorelbine and several other cytotoxic APIs for which oral presentations or oral absorption data are more extensively developed. Formulators evaluating eribulin mesylate for tablets, capsules, or granules should therefore treat first-pass metabolism and intestinal efflux as unresolved experimental issues rather than established design parameters.

For solid-dose preformulation, micromeritic behavior, bulk density, particle-size distribution, and compressibility are controlled as development-specific parameters. No public compendial monograph provides universal D10/D50/D90 limits for eribulin mesylate. Laser-diffraction particle sizing according to USP <429>, bulk and tapped density per USP <616>, and powder flow per USP <1174> are appropriate method platforms; acceptance ranges must be established from batch-to-batch data. This lack of harmonized public data means that direct-compression tablet formulations cannot be specified from literature alone, and granulation studies should include a systematic excipient compatibility matrix.

API Release Testing, Residual Solvent Control, and Elemental Impurity Profiling Under ICH Q6A

Release of pharma-grade eribulin mesylate is defined by a product-specific specification containing identification, assay, related substances, residual solvents, water, microbial enumeration, and, for injectable grade, bacterial endotoxins, sterility, and subvisible particulate matter. The mesylate salt is typically described in supplier certificates of analysis as a white to off-white powder; visual appearance is confirmed against an internal reference, and polymorphic identity is controlled by X-ray powder diffraction when justified by process changes. Chromatographic purity is determined by high-performance liquid chromatography with ultraviolet detection; method validation follows ICH Q2(R1). Organic volatile impurities are controlled by gas chromatography with headspace injection according to ICH Q3C. Elemental impurities are profiled by inductively coupled plasma mass spectrometry and must meet ICH Q3D risk-based limits.

Acceptance criteria for assay, related substances, and residual solvents are product-specific and must be justified by process capability and stability data. The same chemical entity may be released as injectable or oral development grade, but injectable grade requires the additional parenteral quality attributes and a higher environmental control burden during sampling and packaging.

When the Same API Grade Is Selected for Injectable, Tablet, Capsule, and Granule Development

Injectable processing requires aseptic operations, depyrogenation of product-contact surfaces, and validated filtration through appropriate membrane trains; typical manufacturing suites operate under ISO 14644-1 Class 5 unidirectional airflow with adjacent Grade B areas. For a parenteral finished product, the API must meet sterility, bacterial endotoxin, and particulate matter requirements appropriate to the dose and route. The approved intravenous reference product is supplied as a 0.5 mg/mL solution in single-dose vials; the approved dose is 1.4 mg/m² administered intravenously on days 1 and 8 of a 21-day cycle under the relevant oncology indication. That clinical dose should not be directly translated to oral development because first-pass and efflux barriers require separate bioavailability assessment.

For nonsterile oral solid development, capsule and granule intermediates require blending and lubrication. Tablet compression and capsule filling may require dry granulation if direct blend flow and bulk density prove unsuitable; published tabletability data for eribulin mesylate are limited. Any high-shear or roller-compaction process should be designed with residual moisture control and validated under ICH Q8 quality-by-design principles. Handling at relative humidity above 60% should be evaluated for moisture uptake and agglomeration, but this is a general operational warning rather than an eribulin-specific stability limit.

Stability of eribulin mesylate in formulation admixtures should be confirmed under forced degradation conditions described in ICH Q1A(R2). Compatibility with common tonicity modifiers, buffer salts, and oral excipients is not automatically transferable from other cytotoxic APIs; each excipient combination requires experimental verification. Published data for eribulin mesylate in lipid-based oral systems are limited, so no excipient compatibility conclusion can be drawn without site-specific forced degradation and binodal solubility studies.

Controlling Particulate Matter and Endotoxin Burden in Injectable Grade Processing

For injectable grade eribulin mesylate, subvisible particulate matter is controlled by light obscuration according to USP <788>, with Method 1 or Method 2 applied to the final container depending on volume. Endotoxin burden is measured by Limulus amebocyte lysate testing according to Ph. Eur. 2.6.14 and USP <85>. Sterility is demonstrated by membrane filtration per Ph. Eur. 2.6.1 and USP <71>. These tests are release-critical for parenteral products and are not automatically required for oral-grade API; a manufacturer may supply the same chemical entity as either grade, but the quality system must maintain segregation, environmental monitoring, and sampling plans for the injectable grade.

Filtration and filling suites for injectable eribulin mesylate typically operate under ISO 14644-1 Class 5 unidirectional airflow with adjacent Grade B areas, matching the aseptic processing expectations of FDA 21 CFR 210 and 211. Filter compatibility with polyvinylidene fluoride or polyethersulfone membranes must be demonstrated before sterile filtration, because the formulation solvent and pH affect filtrate flux. No conclusion on filter binding or leachable profiles should be transferred from other cytotoxic APIs; each filter train requires validation.

For any change from the commercial injectable formulation to an oral or granulated intermediate, the sponsor must generate site-specific stability, solubility, and permeability data. Published physicochemical data for eribulin mesylate granules, tablet cores, or capsule blends are limited; therefore, universal processing parameters cannot be extracted from regulatory summaries or pharmacopoeial literature.